Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Life Technologies Corporation (NASDAQ:LIFE) today announced results for its third quarter ended September 30, 2009. Non-GAAP revenue for the third quarter was $805 million, an increase of 3 percent over third quarter revenue of $784 million in 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 27 Oct 2009

Metabolon raises additional $6 million in its Series C funding round

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that it has closed an additional $6 million in its Series C funding round. This brings the total funding raised in the company’s series C round to $12.3 million.

27 Oct 2009

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement allowing Eli Lilly and Company (NYSE: LLY) select access to research from its osteoarthritis genomic biomarker program

27 Oct 2009

Catapult BioAccel announces funding of Kemeta

Catapult BioAccel, formerly named CatapultBio, has announced the funding of an Arizona-based early stage firm, Kemeta LLC, a company developing a revolutionary product for application in consumer health and medical markets.

27 Oct 2009

Compugen announces financial results for the third quarter ended September 30, 2009

Compugen Ltd. today reported financial results for the third quarter ended September 30, 2009.

27 Oct 2009

Champions Biotechnology expands collaboration to accelerate oncology drug development

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

27 Oct 2009

Thermo Fisher Scientific announces the availability of its Copeptin assay in Europe

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack.

From Thermo Fisher Scientific Inc. 26 Oct 2009

Comparison study between pre and postoperative BNP measurements for predicting negative outcomes after CABG surgery

Results from a clinical study presented at the 2009 American Society of Anesthesiologists (ASA) Meeting suggest that elevated preoperative levels of the B-type natriuretic peptide (BNP) biomarker may predict hospital length of stay and mortality after primary coronary artery bypass graft surgery better than measurements of elevated postoperative BNP levels.

26 Oct 2009

Set of critical decision points in cancer biomarker and drug development summarized

A commentary published online October 23 in the Journal of the National Cancer Institute summarizes a set of critical decision points in cancer biomarker and drug development. The points, which emerged from a workshop, include developing a clear understanding of the biology of the target and its interaction with the drug and the factors affecting the performance of the biomarker assay.

24 Oct 2009

Physicians' recognize benefits of genetic testing; say formal education required to put it into practice

Medco Health Solutions, Inc.(NYSE: MHS) and the American Medical Association (AMA) today announced the findings of a national benchmark survey on physicians' acceptance, use and education regarding pharmacogenomic testing.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies’ collaboration formed in October 2007.

22 Oct 2009

Life science tool companies must consider multiple factors to develop strategies for future

Companies involved in the life science tools market must consider a multitude of technologies, economic drivers and societal trends in developing strategies for the future.

21 Oct 2009

Tyrian Diagnostics and BD end collaboration to develop a Point-of-Care test for TB diagnosis

Tyrian Diagnostics Limited announced today that Tyrian and BD (Becton, Dickinson and Company) will not continue their collaboration to develop a Point-of-Care (PoC) test for the diagnosis of active tuberculosis (TB).

From BD (Becton, Dickinson and Company) 20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Health Discovery Corporation is pleased to announce numerous additional issued patents and Notices of Allowance since its last press release describing its intellectual property portfolio. The Company now has a total of 37 issued patents, 4 Notices of Allowance and 30 pending patent applications.

20 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

Biomarker News and Research

Further Reading

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Metabolon raises additional $6 million in its Series C funding round

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

Catapult BioAccel announces funding of Kemeta

Compugen announces financial results for the third quarter ended September 30, 2009

Champions Biotechnology expands collaboration to accelerate oncology drug development

Thermo Fisher Scientific announces the availability of its Copeptin assay in Europe

Comparison study between pre and postoperative BNP measurements for predicting negative outcomes after CABG surgery

Set of critical decision points in cancer biomarker and drug development summarized

Physicians' recognize benefits of genetic testing; say formal education required to put it into practice

Early diagnostic for ovarian cancer to be developed

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Life science tool companies must consider multiple factors to develop strategies for future

Tyrian Diagnostics and BD end collaboration to develop a Point-of-Care test for TB diagnosis

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Health Discovery Corporation granted additional patents for Recursive Feature Elimination using Support Vector Machines

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Prometheus Laboratories introduces three new cancer diagnostic products

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News